Solid Biosciences (NASDAQ: SLDB) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Institutional and Insider Ownership
47.7% of Curis shares are owned by institutional investors. 4.1% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Solid Biosciences and Curis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Solid Biosciences and Curis, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Solid Biosciences currently has a consensus price target of $37.33, suggesting a potential upside of 316.67%. Curis has a consensus price target of $7.00, suggesting a potential upside of 885.92%. Given Curis’ stronger consensus rating and higher probable upside, analysts plainly believe Curis is more favorable than Solid Biosciences.
Valuation and Earnings
This table compares Solid Biosciences and Curis’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Solid Biosciences||N/A||N/A||-$21.53 million||N/A||N/A|
|Curis||$9.90 million||11.88||-$53.31 million||($0.37)||-1.92|
Solid Biosciences has higher earnings, but lower revenue than Curis.
Solid Biosciences Company Profile
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.
Curis Company Profile
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.